https://www.yiliao.com/index.php?action=history&feed=atom&title=V561M
V561M - 版本历史
2026-04-18T13:26:14Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=V561M&diff=315594&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-24T23:29:37Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>V561M</strong> 是 <strong>[[FGFR1]]</strong>（Fibroblast Growth Factor Receptor 1）基因酪氨酸激酶结构域第 561 位缬氨酸（Valine）被甲硫氨酸（Methionine）取代的错义突变。该位点位于激酶的 ATP 结合口袋深处，被称为“<strong>[[守门员突变]]</strong>”（Gatekeeper Mutation）。在临床上，V561M 通常作为<strong>[[获得性耐药]]</strong>机制出现，导致患者对第一代 ATP 竞争性 FGFR 抑制剂（如<strong>[[佩米替尼]]</strong>、<strong>[[英菲格拉替尼]]</strong>）产生耐药。然而，这一突变无法阻挡<strong>[[富替巴替尼]]</strong>（Futibatinib）等下一代共价抑制剂的结合，因此 V561M 阳性患者仍有明确的挽救治疗方案。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">FGFR1 V561M</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Gatekeeper Resistance (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[[Image:Gatekeeper_mutation_FGFR1_V561M_mechanism.png|100px|V561M 导致的空间位阻示意]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">FGFR1 的耐药关卡</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">所属基因</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;"><strong>[[FGFR1]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">突变性质</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>[[守门员突变]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">耐药药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #64748b;">[[佩米替尼]] (Pemigatinib)<br>[[英菲格拉替尼]] (Infigratinib)<br>[[厄达替尼]] (Erdafitinib)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">敏感药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #166534;"><strong>[[富替巴替尼]]</strong> (Futibatinib)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">相关疾病</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">肺鳞癌, 骨髓增殖性肿瘤</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">同源突变</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">FGFR2 [[V564M]]<br>EGFR [[T790M]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">检测方法</th><br />
<td style="padding: 6px 12px; color: #0f172a;">液体活检 [[NGS]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：口袋深处的路障</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
V561M 的耐药机制是经典的“空间位阻”效应，与 EGFR T790M 高度相似。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>守门员位置 (The Gatekeeper)：</strong><br />
<br>第 561 位的缬氨酸（Valine）位于连接激酶 N 叶和 C 叶的铰链区附近，控制着通往激酶深层疏水口袋（Hydrophobic pocket）的入口。</li><br />
<li style="margin-bottom: 12px;"><strong>侧链冲突：</strong><br />
<br>当缬氨酸突变为侧链更长的<strong>甲硫氨酸</strong>（Methionine）时，侧链体积增大。<br />
<br>• <strong>ATP 结合不受影响：</strong> 甲硫氨酸虽然大，但并没有大到阻止天然底物 ATP 的结合，因此突变后的激酶依然具有活性（甚至活性增强）。<br />
<br>• <strong>药物结合受阻：</strong> 第一代可逆抑制剂（如[[佩米替尼]]）通常需要深入疏水口袋以获得高亲和力。V561M 的侧链直接占据了这个空间，将药物“顶”在门外，导致亲和力下降数百倍。</li><br />
</ul><br />
<br />
<h2 style="background: #fff1f2; color: #9f1239; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #9f1239; font-weight: bold;">临床对策：不可逆抑制剂的胜利</h2><br />
<div style="background-color: #fff5f5; border-left: 5px solid #e11d48; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #be123c; font-size: 1.1em;">换把“锁”，开这扇门</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
针对 V561M 耐药，药物化学家开发了<strong>[[共价抑制剂]]</strong>（Covalent Inhibitors），其代表药物是 <strong>[[富替巴替尼]]</strong>（Futibatinib, TAS-120）。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">药物类型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 35%;">结合模式</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; width: 40%;">对 V561M 疗效</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>可逆抑制剂</strong><br>(佩米替尼/英菲格拉替尼)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">ATP 竞争性结合<br>(依赖疏水口袋)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #b91c1c;"><strong>耐药</strong><br>(IC50 显著升高)</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;"><strong>不可逆(共价)抑制剂</strong><br>(富替巴替尼)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">与 P-loop 上的 <strong>Cysteine</strong> 形成共价键</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #166534;"><strong>敏感</strong><br>不依赖疏水口袋深处，能克服位阻。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">家族同源性：不止 FGFR1</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
FGFR 家族高度保守，V561M 在其他亚型中都有对应的“双胞胎”耐药位点，治疗策略也高度一致。<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>FGFR1 V561M：</strong> 常见于肺鳞癌（FGFR1 扩增）和 8p11 骨髓增殖性综合征（EMS）。</li><br />
<li style="margin-bottom: 12px;"><strong>FGFR2 V564M：</strong> 常见于<strong>[[胆管癌]]</strong>（FGFR2 融合）患者使用佩米替尼治疗后。</li><br />
<li style="margin-bottom: 12px;"><strong>FGFR3 V555M：</strong> 常见于<strong>[[尿路上皮癌]]</strong>（FGFR3 突变/融合）患者使用厄达替尼治疗后。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Goyal L, Meric-Bernstam F, Bahleda R, et al. (2019).</strong> <em>Futibatinib Phase I Study in Patients with Advanced Solid Tumors.</em> <strong>[[Cancer Discovery]]</strong>. 2019.<br><br />
<span style="color: #475569;">[临床突破]：该研究证实了富替巴替尼对携带 V561M (FGFR1) 或 V564M (FGFR2) 等守门员突变的患者具有显著的抗肿瘤活性。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Sohal SS, et al. (2019).</strong> <em>Structural basis for the efficacy of futibatinib (TAS-120) against FGFR inhibitor-resistant mutations.</em> <strong>[[Molecular Cancer Therapeutics]]</strong>.<br><br />
<span style="color: #475569;">[机制解析]：通过晶体结构分析，揭示了富替巴替尼独特的柔性 P-loop 结合模式，解释了其为何能规避守门员突变带来的空间位阻。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Cowell JK, et al. (2018).</strong> <em>Mechanisms of resistance to FGFR inhibitors.</em> <strong>[[Journal of Experimental & Clinical Cancer Research]]</strong>.<br><br />
<span style="color: #475569;">[综述]：系统总结了 FGFR 抑制剂的耐药图谱，将 V561M 定义为该靶点最核心的获得性耐药机制之一。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
FGFR1 V561M · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">突变角色</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[守门员突变]]</strong> (Gatekeeper) • 抗一代药/敏二代药</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">同类类比</td><br />
<td style="padding: 10px 15px; color: #334155;">FGFR2 [[V564M]] • EGFR [[T790M]] • KIT [[T670I]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">特效药物</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[富替巴替尼]]</strong> (Futibatinib) • 共价结合</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">耐药后</td><br />
<td style="padding: 10px 15px; color: #334155;">可能出现 N546K (分子制动器) 突变或旁路激活</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020